Breast Cancer Survival Rates: Prognosis by Age, Race & More
Prognostic factors in epithelial ovarian cancer: A population-based study | PLOS ONE
Diagnostics | Free Full-Text | Prognostic Factors Associated with 5-Year Overall Survival in Cervical Cancer Patients Treated with Radical Hysterectomy Followed by Adjuvant Concurrent Chemoradiation Therapy at a Tertiary Care Center in
Cancer patient survival can be parametrized to improve trial precision and reveal time-dependent therapeutic effects | Nature Communications
Overall survival of patients with metastatic breast cancer in Sweden: a nationwide study | British Journal of Cancer
Kaplan-Meier survival curves of a progression-free survival (PFS) and b... | Download Scientific Diagram
Progress in cancer survival, mortality, and incidence in seven high-income countries 1995–2014 (ICBP SURVMARK-2): a population-based study - The Lancet Oncology
Retrospective observational cohort study on innovation in oncology and progress in survival: How far have we gotten in the two decades of treating patients with advanced non-small cell lung cancer as a
Progression-free survival as a surrogate endpoint for overall survival in modern ovarian cancer trials: a meta-analysis - Katrin M. Sjoquist, Sarah J. Lord, Michael L. Friedlander, Robert John Simes, Ian C. Marschner,
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer | NEJM
Pancancer survival analysis of cancer hallmark genes | Scientific Reports
Breast Cancer Survival Rates: Prognosis by Age, Race & More
Frontiers | Analysis of Survival Curves: Statistical Methods Accounting for the Presence of Long-Term Survivors
Figure 1 from Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. | Semantic Scholar
Kaplan-Meier curve of progression-free survival (PFS) (a) and overall... | Download Scientific Diagram
Overall survival according to immunotherapy and radiation treatment for metastatic non-small-cell lung cancer: a National Cancer Database analysis | Radiation Oncology | Full Text
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer | NEJM
Understanding Survival Analysis in Clinical Trials - Clinical Oncology
Cancers | Free Full-Text | Artificial Intelligence Predicted Overall Survival and Classified Mature B-Cell Neoplasms Based on Immuno-Oncology and Immune Checkpoint Panels
Comparison of patterns and prognosis among distant metastatic breast cancer patients by age groups: a SEER population-based analysis | Scientific Reports
5-year overall survival in patients with lung cancer eligible or ineligible for screening according to US Preventive Services Task Force criteria: a prospective, observational cohort study - The Lancet Oncology
The role of censoring on progression free survival: Oncologist discretion advised - ScienceDirect
Median Overall Survival (mOS) | ENHERTU® (fam-trastuzumab deruxtecan-nxki)